Action Point Financial Planning’s Amneal Pharmaceuticals AMRX Stock Holding History

Action Point Financial Planning’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.52K	Buy	+90	New	+$1.23K	﹤0.01%	2352

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Action Point Financial Planning's AMRX Position: Q2 2026 in Review

Action Point Financial Planning opened a new position in Amneal Pharmaceuticals (AMRX) in Q2 2026: 90 shares worth $1.52K. The stake represents ﹤0.01% of the portfolio and ranks #2352 among its holdings.

305 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Action Point Financial Planning held 90 shares of Amneal Pharmaceuticals worth $1.52K as of Q2 2026.
Amneal Pharmaceuticals was a new Action Point Financial Planning position in Q2 2026.
Amneal Pharmaceuticals made up ﹤0.01% of Action Point Financial Planning's portfolio in Q2 2026, its #2352 holding.
305 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Action Point Financial Planning's 13F filing for Q2 2026, filed 14 Aug 2026.